 MINNEAPOLIS, MN ACCESSWIRE March 1, 2021 Celcuity Inc. NASDAQ:CELC, a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, today announced the closing, on February 26, 2021, of its previously announced underwritten public offering of 1,971,100 shares of its common stock, including 257,100 shares of its common stock sold pursuant to the full exercise by the underwriter of its option to purchase additional shares of common stock to cover over-allotments, if any. All of the shares were sold at a price to the public of 14.00 per share. 